Kura Oncology, Inc.
DE ˙ DB ˙ US50127T1097
7,56 € ↑0,24 (3,28%)
2026-06-05
DEL PRIS
SecurityDE:KUR / Kura Oncology, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership1,425,945 shares
Latest Disclosed Value $ 11,590,675
Dimensional Fund Advisors Lp reports 32.30% increase in ownership of KUR / Kura Oncology, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 1,425,945 shares of Kura Oncology, Inc. (DE:KUR) valued at $9,482,534 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 1,077,818 shares of Kura Oncology, Inc.. This represents a change in shares of 32.30% during the quarter. The current value of the position is $10,780,144 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F KURA ONCOLOGY COM 50127T109 1,425,945 348,127 32.30 11,591 3.51 0.0024
2026-02-12 2025-12-31 13F KURA ONCOLOGY COM 50127T109 1,077,818 -61,547 -5.40 11,197 11.05 0.0023
2025-11-12 2025-09-30 13F KURA ONCOLOGY COM 50127T109 1,139,365 -103,567 -8.33 10,084 40.61 0.0022
2025-08-12 2025-06-30 13F KURA ONCOLOGY COM 50127T109 1,242,932 -119,492 -8.77 7,171 -20.26 0.0017
2025-05-13 2025-03-31 13F KURA ONCOLOGY COM 50127T109 1,362,424 -63,536 -4.46 8,994 -27.59 0.0022
2025-02-13 2024-12-31 13F KURA ONCOLOGY COM 50127T109 1,425,960 372,196 35.32 12,419 -39.68 0.0030
2024-11-07 2024-09-30 13F KURA ONCOLOGY COM 50127T109 1,053,764 159,145 17.79 20,591 11.78 0.0050
2024-08-09 2024-06-30 13F KURA ONCOLOGY COM 50127T109 894,619 -468,816 -34.38 18,420 -36.66 0.0048
2024-05-10 2024-03-31 13F KURA ONCOLOGY COM 50127T109 1,363,435 -638,319 -31.89 29,082 1.04 0.0079
2024-02-07 2023-12-31 13F KURA ONCOLOGY COM 50127T109 2,001,754 197,530 10.95 28,785 74.95 0.0084
2023-11-09 2023-09-30 13F KURA ONCOLOGY COM 50127T109 1,804,224 -107,432 -5.62 16,454 -18.65 0.0054
2023-08-09 2023-06-30 13F KURA ONCOLOGY COM 50127T109 1,911,656 76,572 4.17 20,224 -9.88 0.0064
2023-05-12 2023-03-31 13F KURA ONCOLOGY COM 50127T109 1,835,084 133,912 7.87 22,442 106,761.90 0.0076
2023-02-09 2022-12-31 13F KURA ONCOLOGY COM 50127T109 1,701,172 128,515 8.17 21 -99.90 0.0062
2022-11-10 2022-09-30 13F KURA ONCOLOGY COM 50127T109 1,572,657 193,042 13.99 21,482 -15.05 0.0082
2022-08-12 2022-06-30 13F KURA ONCOLOGY COM 50127T109 1,379,615 308,930 28.85 25,287 46.87 0.0091
2022-05-13 2022-03-31 13F KURA ONCOLOGY COM 50127T109 1,070,685 296,175 38.24 17,217 58.77 0.0053
2022-02-09 2021-12-31 13F KURA ONCOLOGY COM 50127T109 774,510 124,269 19.11 10,844 -10.96 0.0033
2021-11-12 2021-09-30 13F KURA ONCOLOGY COM 50127T109 650,241 -110,066 -14.48 12,179 -23.18 0.0039
2021-08-12 2021-06-30 13F KURA ONCOLOGY COM 50127T109 760,307 -58,785 -7.18 15,854 -31.38 0.0050
2021-05-14 2021-03-31 13F KURA ONCOLOGY COM 50127T109 819,092 170,582 26.30 23,104 9.07 0.0076
2021-03-08 2020-12-31 13F/A-2 KURA ONCOLOGY COM 50127T109 648,510 26,046 4.18 21,183 11.07 0.0076
2021-02-11 2020-12-31 13F KURA ONCOLOGY COM 50127T109 648,510 26,046 21,183 7,650.1737
2020-11-12 2020-09-30 13F KURA ONCOLOGY COM 50127T109 622,464 30,369 5.13 19,072 97.60 0.0081
2020-08-13 2020-06-30 13F KURA ONCOLOGY COM 50127T109 592,095 39,186 7.09 9,652 75.49 0.0042
2020-05-14 2020-03-31 13F KURA ONCOLOGY COM 50127T109 552,909 7,872 1.44 5,500 -26.62 0.0029
2020-02-14 2019-12-31 13F KURA ONCOLOGY COM 50127T109 545,037 7,180 1.33 7,495 -8.13 0.0027
2019-11-12 2019-09-30 13F KURA ONCOLOGY COM 50127T109 537,857 4,450 0.83 8,158 -22.33 0.0032
2019-08-13 2019-06-30 13F KURA ONCOLOGY COM 50127T109 533,407 142,414 36.42 10,503 61.93 0.0041
2019-08-12 2019-03-31 13F/A-2 KURA ONCOLOGY COM 50127T109 390,993 232,733 147.06 6,486 191.90 0.0026
2019-05-10 2019-03-31 13F KURA ONCOLOGY COM 50127T109 390,993 232,733 6,486
2019-02-26 2018-12-31 13F/A-1 KURA ONCOLOGY COM 50127T109 158,260 158,260 2,222 0.0010
2019-02-13 2018-12-31 13F KURA ONCOLOGY COM 50127T109 158,260 2,222 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.